References
- Abraham, A., Ziv, I., Steinmetz, A., Groshar, D., & Djaldetti, R. (2010, February 16). Autoimmune polyendocrine syndrome type I and brain calcinosis. Parkinsonism Relat Disord, 16(2), 101–104. https://doi.org/https://doi.org/10.1016/j.parkreldis.2009.07.014
- Adami, S., Marcocci, C., & Gatti, D. (2002, November). Epidemiology of primary hyperparathyroidism in Europe. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 17(Suppl 2), N18–23.
- Agarwal, R., Lahiri, D., Biswas, A., Mukhopadhyay, J., Maity, P., & Roy, M. K. (2014, October). A rare cause of seizures, parkinsonian, and cerebellar signs: Brain calcinosis secondary to thyroidectomy. North American Journal of Medical Sciences, 6(10), 540–542. https://doi.org/https://doi.org/10.4103/1947-2714.143287
- Augusto, C. M. G., de Morais, N. S., Santana, R. P., & de Almeida, M. O. P. (2019, Jul-August). PARKINSONISM AS AN ATYPICAL MANIFESTATION OF PRIMARY HYPERPARATHYROIDISM. AACE Clinical Case Reports, 5(4), e244–e6. https://doi.org/https://doi.org/10.4158/ACCR-2018-0504
- Bilezikian, J. P., Brandi, M. L., Eastell, R., Silverberg, S. J., Udelsman, R., Marcocci, C., & Potts, J. T., Jr. (2014, October). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3561–3569. https://doi.org/https://doi.org/10.1210/jc.2014-1413
- Bilezikian, J. P., Khan, A. A., & Potts, J. T., Jr. (2009, February). Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. The Journal of Clinical Endocrinology & Metabolism, 94(2), 335–339. https://doi.org/https://doi.org/10.1210/jc.2008-1763
- Bofill-Cardona, E., Kudlacek, O., Yang, Q., Ahorn, H., Freissmuth, M., & Nanoff, C. (2000, October 20). Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch. Journal of Biological Chemistry, 275(42), 32672–32680. https://doi.org/https://doi.org/10.1074/jbc.M002780200
- Cogan, M. G., Covey, C. M., Arieff, A. I., Wisniewski, A., Clark, O. H., Lazarowitz, V., & Leach, W. (1978, December). Central nervous system manifestations of hyperparathyroidism. The American Journal of Medicine, 65(6), 963–970. https://doi.org/https://doi.org/10.1016/0002-9343(78)90748-9
- de la Plaza Llamas, R., Ramia Ángel, J. M., Arteaga Peralta, V., Hernández Cristóbal, J., & López Marcano, A. J. (2016, January). Brain calcifications and primary hyperparathyroidism. Cirugia espanola, 94(1), e5–7. https://doi.org/https://doi.org/10.1016/j.ciresp.2015.08.003
- De Rosa, A., Rinaldi, C., Tucci, T., Pappatà, S., Rossi, F., Morra, V. B., Faggiano, A., Colao, A., & De Michele, G. (2011, December). Co-existence of primary hyperparathyroidism and Parkinson’s disease in three patients: An incidental finding? Parkinsonism Relat Disord, 17(10), 771–773. https://doi.org/https://doi.org/10.1016/j.parkreldis.2011.04.021
- Donzuso, G., Sciacca, G., Nicoletti, A., Mostile, G., Patti, F., & Zappia, M. (2016, September). Extensive bilateral striopallidodentate calcinosis: A 50 years history of hypoparathyroidism presenting like a parkinsonian syndrome. J Neurol, 263(9), 1876–1879. https://doi.org/https://doi.org/10.1007/s00415-016-8243-8
- Gaba, S., Singla, M., Gupta, M., Dua, A., & Gaba, N. (2020, September 26). From psychiatry to neurology and endocrinology: A case of hypoparathyroidism. Cureus, 12(9), e10666. https://doi.org/https://doi.org/10.7759/cureus.10666
- Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J. E., Rejnmark, L., Thakker, R., D’Amour, P., Paul, T., Van Uum, S., Shrayyef, M. Z., Goltzman, D., Kaiser, S., Cusano, N. E., Bouillon, R., Mosekilde, L., Kung, A. W., Rao, S. D., Bhadada, S. K., and Bilezikian, J. P. (2017, January). Primary hyperparathyroidism: Review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int, 28(1), 1–19. https://doi.org/https://doi.org/10.1007/s00198-016-3716-2
- Klawans, H. L., Lupton, M., & Simon, L. (1976, March). Calcification of the basal ganglia as a cause of levodopa-resistant Parkinsonism. Neurology, 26(3), 221–225. https://doi.org/https://doi.org/10.1212/WNL.26.3.221
- Knuth, W. P, Kisner, Paul. (1956). SYMMETRICAL CEREBRAL CALCIFICATION ASSOCIATED WITH PARATHYROID ADENOMA. Journal of the American Medical Association, 162(5), 462–464. https://doi.org/https://doi.org/10.1001/jama.1956.72970220004006b
- Kovacs, C. S., Howse, D. C., & Yendt, E. R. (1993, May 10). Reversible parkinsonism induced by hypercalcemia and primary hyperparathyroidism. Archives of Internal Medicine, 153(9), 1134–1136. https://doi.org/https://doi.org/10.1001/archinte.1993.00410090076010
- Macfarlane, D. P., Yu, N., & Leese, G. P. (2015, May). Asymptomatic and mild primary hyperparathyroidism. Ann Endocrinol (Paris), 76(2), 120–127. https://doi.org/https://doi.org/10.1016/j.ando.2015.03.001
- Maghraoui, A., Birouk, N., Zaim, A., Slassi, I., & Chkili, T.(1995). Fahr syndrome and dysparathyroidism. 3 cases. Presse Med, 24(28), 1301–1304 .
- Manea, M. M., Sirbu, A., Dragos, D., Dobri, A. M., Sirbu, A. G., & Tuta, S. (2020, Jul-September). EPILEPTIC SEIZURES AS THE FIRST MANIFESTATION OF FAHR’S SYNDROME. Acta Endocrinologica (Bucharest, Romania: 2005), 16(3), 370–374. https://doi.org/https://doi.org/10.4183/aeb.2020.370
- Margolin, D., Hammerstad, J., Orwoll, E., Mcclung, M., & Calhoun, D. (1980). Intracranial calcification in hyperparathyroidism associated with gait apraxia and parkinsonism. Neurology, 30(9), 1005–1007. https://doi.org/https://doi.org/10.1212/WNL.30.9.1005
- Orwoll, E. S., Margolin, D. I., & Hammerstad, J. P. (1981). Hyperparathyroidism and intracerebral calcification. Biochemical Society Transactions, 9(1), 273–279. https://doi.org/https://doi.org/10.1042/bst0090050
- Ozisik, H., Yürekli, B. S., Tuncel, R., Ozdemir, N., Baklaci, M., Ekmekci, O., & Saygili, F. (2020, Jan-March). PSEUDOPSEUDOHYPOPARATHYROIDISM AS A CAUSE OF FAHR SYNDROME: HYPOPARATHYROIDISM NOT THE ONLY ONE. Acta Endocrinologica (Bucharest, Romania: 2005), 16(1), 86–89. https://doi.org/https://doi.org/10.4183/aeb.2020.86
- PA, Fitzgerald, Ed. (2019). Endocrine disorders. In Current medical diagnosis & treatment 2019 (pp. 1119–1220). McGraw-Hill Education.
- Wilhelm, S. M., Wang, T. S., Ruan, D. T., Lee, J. A., Asa, S. L., Duh, Q. Y., Doherty, G. M., Herrera, M. F., Pasieka, J. L., Perrier, N. D., Silverberg, S. J., Solórzano, C. C., Sturgeon, C., Tublin, M. E., Udelsman, R., & Carty, S. E. (2016, October 1). The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surgery, 151(10), 959–968. https://doi.org/https://doi.org/10.1001/jamasurg.2016.2310